Summary

The product HGH, manufactured by Lemon@arailpharma.me and submitted by Arail Pharmaceuticals, underwent independent testing to verify its composition and purity. The sample, identified by batch number 1, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The test confirmed that the vial contained 3.79 mg (11.37 IU) of recombinant Human Growth Hormone (rHGH), with a purity of 95.823%. No dimer or related proteins were detected, indicating a clean sample.

The testing process began on 5 November 2024, with the sample received on 15 November 2024, and analysis completed on 22 November 2024.


Detailed Report

Product Overview

Testing Details

Testing Results


Verification Details


Evaluation of Manufacturer-Submitted Testing

The test confirms that the HGH sample contains 3.79 mg (11.37 IU) of rHGH with high purity and no detected impurities. While this is a positive indicator of product quality, it remains a single-batch test submitted by a manufacturer. For a more comprehensive assessment, multiple batch tests and independent third-party verification are recommended.


Conclusion

The test confirms that the HGH product contains the expected recombinant Human Growth Hormone with a high purity of 95.823%, and no impurities were detected. However, further independent testing across multiple batches is advised to ensure consistency.


Disclaimer

This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may have inherent biases, but it still provides valuable insights when cross-checked with independent analysis. Readers should interpret this information critically and responsibly.